ConnollySJ, et al.Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 2009; 361:1139–1151.
2.
GiuglianoRP, et al.Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2013; 369:2093–2104.
3.
GrangerCB, et al.Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011; 365:981–992.
4.
PatelMR, et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 2011; 365:883–891.
5.
LipGY, et al.Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol, 2012; 60:738–746.
6.
SchneeweissS, et al.Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes, 2012; 5:480–486.
7.
PancholySB, et al.Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants. Am J Cardiol, 2014; 113:485–490.
8.
MoselyA, et al.Indirect Comparison of Novel Oral Anticoagulants in Women with Non-valvular Atrial Fibrillation. J Womens Health, 2017; 26:214–221.
9.
LoffredoL, VioliF, PerriL. Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants. A meta-analysis of the interventional trials. Int J Cardiol, 2016; 212:255–258.
10.
BucherHC, et al.The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol, 1997; 50:683–691.
11.
MelloniC, et al.Representation of women in randomized clinical trials of cardiovascular disease prevention. Circ Cardiovasc Qual Outcomes, 2010; 3:135–142.
12.
GibsonCM, et al.Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med, 2016; 375:2423–2434.
